155 related articles for article (PubMed ID: 15618031)
1. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy.
Walldius G; Jungner I
Eur Heart J; 2005 Feb; 26(3):210-2. PubMed ID: 15618031
[No Abstract] [Full Text] [Related]
2. Apolipoproteins A-I and B-markers in coronary risk evaluation.
Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
[TBL] [Abstract][Full Text] [Related]
3. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
4. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
Walldius G; Jungner I
J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
[TBL] [Abstract][Full Text] [Related]
5. Which lipid measures are prognostic indicators of cardiovascular disease in women?
Oettgen P
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):190-1. PubMed ID: 16932280
[No Abstract] [Full Text] [Related]
6. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
Walldius G; Jungner I
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
[TBL] [Abstract][Full Text] [Related]
7. [Should apolipoproteins be the first choice in routine health care?].
Järhult B; Lindström K
Lakartidningen; 2007 Oct 17-23; 104(42):3124. PubMed ID: 17985715
[No Abstract] [Full Text] [Related]
8. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.
Lind L; Vessby B; Sundström J
Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):406-10. PubMed ID: 16306426
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study.
Meisinger C; Loewel H; Mraz W; Koenig W
Eur Heart J; 2005 Feb; 26(3):271-8. PubMed ID: 15618061
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study.
Pitsavos C; Panagiotakos DB; Skoumas J; Papadimitriou L; Stefanadis C
Angiology; 2008; 59(3):335-41. PubMed ID: 18388068
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein B/A1 and risk of cardiovascular disease.
Lind L
Lancet; 2008 Jul; 372(9634):185-6. PubMed ID: 18640440
[No Abstract] [Full Text] [Related]
13. Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease.
Sniderman AD; Holme I; Aastveit A; Furberg C; Walldius G; Jungner I
Am J Cardiol; 2007 Jul; 100(2):217-21. PubMed ID: 17631073
[TBL] [Abstract][Full Text] [Related]
14. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
15. Targets for LDL-lowering therapy.
Sniderman A
Curr Opin Lipidol; 2009 Aug; 20(4):282-7. PubMed ID: 19474729
[TBL] [Abstract][Full Text] [Related]
16. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.
Walldius G; Aastveit AH; Jungner I
J Intern Med; 2006 Mar; 259(3):259-66. PubMed ID: 16476103
[TBL] [Abstract][Full Text] [Related]
17. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.
Marcovina S; Packard CJ
J Intern Med; 2006 May; 259(5):437-46. PubMed ID: 16629849
[TBL] [Abstract][Full Text] [Related]
18. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
Faergeman O
J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848
[No Abstract] [Full Text] [Related]
19. Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment.
Vaverkova H; Frohlich J; Jackuliakova D; Novotny D
Clin Biochem; 2005 Jun; 38(6):509-13. PubMed ID: 15885228
[TBL] [Abstract][Full Text] [Related]
20. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome.
Sierra-Johnson J; Somers VK; Kuniyoshi FH; Garza CA; Isley WL; Gami AS; Lopez-Jimenez F
Am J Cardiol; 2006 Nov; 98(10):1369-73. PubMed ID: 17134631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
